ZURICH Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline.
Basel-based Novartis will make an initial upfront payment of $300 million to GSK for the acquisition of the compound and a further $200 million payable following the start of a phase III study in MS by Novartis.
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner6
20:28 With Europe-Canada Deal Near Collapse, Globalization’s Latest Chapter Is History4
11:10 Merged BAT-Reynolds could be loaded with up to $55 billion of debt, analysts say5
23:06 AT&T discussed takeover in meetings with Time Warner: Bloomberg